SUTRO BIOPHARMA, INC.
Close on Oct 19, 2026
- Market cap
- $186.51M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | $9.80M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | During market hours | $14.50M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $9.70M | $-0.67 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | $-0.14 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | During market hours | $17.40M | $-0.91 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $8.50M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Mar 13, 2025, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Cash payments resulting from the strategic portfolio review and related restructuring | future | $40.00M to $45.00M | – |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Sutro Biopharma filed with the SEC
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
August 2026 NASDAQ: STRO Exhibit 99.2 Sutro Biopharma Logo
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
Agreement terminated · Results of operations · EX-99.1 to Form 8-K
statements of historical fact contained in this presentation, including information concerning our future financial performance; business plans and objectives; anticipated preclinical and clinical development activities, including enrollment and
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights
Results of operations · Exit or restructuring costs · Executive or director change · EX-99.1 to Form 8-K
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
Results of operations · Exit or restructuring costs · Executive or director change · EX-99.2 to Form 8-K
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Intended for international media and investor audiences only
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Company Overview January 2024 Sutro Biopharma NASDAQ: STRO Exhibit 99.1
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K